[go: up one dir, main page]

AR002024A1 - Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas. - Google Patents

Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.

Info

Publication number
AR002024A1
AR002024A1 ARP960101201A AR10120196A AR002024A1 AR 002024 A1 AR002024 A1 AR 002024A1 AR P960101201 A ARP960101201 A AR P960101201A AR 10120196 A AR10120196 A AR 10120196A AR 002024 A1 AR002024 A1 AR 002024A1
Authority
AR
Argentina
Prior art keywords
xaa
leu
ser
val
thr
Prior art date
Application number
ARP960101201A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002024A1 publication Critical patent/AR002024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen proteínas anti-obesidad, que regulan el tejido adiposo cuando se administran al paciente, con lo cual es posible solucionar y/o prevenir losriesgos colaterales, debido a los estados de diabetes tipo II, cáncer o enfermedades cardiovasculares, asociados con la obesidad. Se trata de proteínasque tienen la secuencia (SEQ ID NO: 1) Val Pro Ile Xaa Lys Val Xaa Asp Asp Thr Lys Thr Leu Ile Lys ThrIle Val Thr Arg Ile Xaa Asp Ile Ser His XaaXaa Ser Val Ser Ser Lys Xaa Lys Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro IleLeu Thr Leu Ser Lys Xaa Asp Xaa Thr Leu Ala Val Tyr Xaa Xaa Ile Leu Thr Ser Xaa Pro Ser Arg Xaa Val Ile Xaa Ile Ser Xaa LeuGluc Xaa LeuArg Asp Leu Leu His Val Leu Ala Phe Ser Lys Ser Cys His Lue Pro Xaa Ala Ser Gly Leu Glu Thr Leu Xaa Ser Leu Gly GlyVal Leu Glu Ala Ser Gly Tyr Ser Thr Val Val Ala Leu Ser Arg Leu Xaa Gly Ser Leu Asp Xaa Leu Xaa XaaLeu Asp Leu Ser Pro Gly CysLas referencias numéricas están ilustradas en la descripción y 1era. reinvidicación.
ARP960101201A 1995-01-31 1996-01-30 Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas. AR002024A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38104895A 1995-01-31 1995-01-31
US38363895A 1995-02-06 1995-02-06

Publications (1)

Publication Number Publication Date
AR002024A1 true AR002024A1 (es) 1998-01-07

Family

ID=27009220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101201A AR002024A1 (es) 1995-01-31 1996-01-30 Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.

Country Status (11)

Country Link
EP (2) EP0725078A1 (es)
JP (1) JPH10513450A (es)
AR (1) AR002024A1 (es)
AU (1) AU4766196A (es)
CA (1) CA2211664A1 (es)
CO (1) CO4480036A1 (es)
FI (1) FI973162A7 (es)
PE (1) PE15297A1 (es)
TR (1) TR199600084A2 (es)
WO (2) WO1996023515A1 (es)
YU (1) YU5396A (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357096A (ja) * 1986-08-29 1988-03-11 工業技術院長 紐体切断装置
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
EP0736599A3 (en) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
CA2221303A1 (en) * 1995-05-19 1996-11-21 Dennis Paul Smith Obesity gene product
AU5800696A (en) * 1995-05-26 1996-12-11 Eli Lilly And Company Rhesus ob protein and dna
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
WO1997011192A1 (en) * 1995-09-19 1997-03-27 Eli Lilly And Company Dna encoding medicinal proteins
US6225446B1 (en) 1995-12-06 2001-05-01 Schering Corporation Mutational variants of mammalian proteins
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
EP0784982A3 (en) * 1996-01-19 1999-08-18 Eli Lilly And Company Obesity protein formulations
AU1705197A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
AU2243997A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
EP0889737A1 (en) * 1996-02-06 1999-01-13 Eli Lilly And Company Obesity protein compounds and formulations thereof
HUP0000280A3 (en) * 1996-03-01 2002-09-30 Amgen Inc Thousand Oaks Canine ob protein compositions and methods
JP2000509018A (ja) * 1996-03-26 2000-07-18 イーライ・リリー・アンド・カンパニー 肥満タンパク質製剤
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
AU4160597A (en) * 1996-08-23 1998-03-06 Eli Lilly And Company Protein formulations
WO1998016545A1 (en) * 1996-10-11 1998-04-23 Eli Lilly And Company Therapeutic proteins
AU5654998A (en) * 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
EP0973535A1 (en) * 1996-12-20 2000-01-26 Eli Lilly And Company Protein crystals, their preparation and use
CA2217698A1 (en) * 1996-12-20 1998-06-20 Eli Lilly And Company Anti-obesity proteins
WO1998028414A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
WO1998031390A1 (en) * 1997-01-17 1998-07-23 Eli Lilly And Company Obesity protein formulations
WO1998036767A1 (en) * 1997-02-25 1998-08-27 Eli Lilly And Company Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands
US5965521A (en) * 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU1134000A (en) * 1998-10-27 2000-05-15 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
JP2005506994A (ja) 2001-10-22 2005-03-10 アムジェン インコーポレイテッド ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1669350B1 (en) 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
CA2629018C (en) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010054017A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
DE102012106607B4 (de) 2012-07-20 2024-04-04 Heliatek Gmbh Verfahren zur Versiegelung von Modulen mit optoelektronischen Bauelementen
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
US10775386B2 (en) 2016-09-12 2020-09-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
IL283182B2 (en) 2018-11-20 2025-10-01 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
KR102553984B1 (ko) * 2020-03-11 2023-07-11 애니젠 주식회사 신규한 화합물을 포함하는 항당뇨 및 항비만용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
IL105406A (en) * 1992-04-17 2000-01-31 Sankyo Co Derivatives of adipogenesis inhibitory factor processes for the preparation thereof and pharmaceutical compositions containing the same
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
FI973162A0 (fi) 1997-07-30
FI973162L (fi) 1997-09-30
JPH10513450A (ja) 1998-12-22
PE15297A1 (es) 1997-05-22
CO4480036A1 (es) 1997-07-09
WO1996023517A1 (en) 1996-08-08
AU4766196A (en) 1996-08-21
FI973162A7 (fi) 1997-09-30
EP0725078A1 (en) 1996-08-07
TR199600084A2 (tr) 1996-08-21
WO1996023515A1 (en) 1996-08-08
EP0725079A1 (en) 1996-08-07
CA2211664A1 (en) 1996-08-08
YU5396A (sh) 1998-08-14

Similar Documents

Publication Publication Date Title
AR002024A1 (es) Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.
KR101956579B1 (ko) 상아질 지각과민증 완화를 위한 치약 조성물
BR9908749A (pt) Composições e formulações de peptìdios e uso das mesmas
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
EP1884247A3 (en) Gastrin compositions and formulations, and methods of use and preparation
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
AU4371799A (en) Lysine containing peptides for treatment of heart disease
NO20053860L (no) COP 1 for behandling av inflammatorisk tarmsykdom.
BR9607336A (pt) Composições de aminoácidos e utilidades das mesmas em nutrição clinica
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
WO1997015598A1 (fr) Nouveau peptide
JPWO1997015598A1 (ja) 新規ペプチド
KR950702579A (ko) 트롬빈 억제제(thrombin inhibitors)
CA2266346A1 (en) Use of proteins as agents against autoimmune diseases
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
NO975565L (no) Benstimulerende faktor
Ferreira et al. Structure and effects of a kinin potentiating fraction F (AppF) isolated from Agkistrodon piscivorus piscivorus venom
NO991653D0 (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
Caffrey Enkephalin/catecholamine interactions in cardiac, skeletal, and intestinal muscle
AU2002365974A1 (en) Alpha-fetoprotein peptides and uses thereof
BR0007816A (pt) Fator de estimulação óssea
IL115825A0 (en) Therapeutic protein
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
Mårvik et al. Effect of cionin on histamine and acid secretion by the perfused rat stomach
TH34900A (th) โปรตีนยับยั้งความอ้วน